article thumbnail

STAT+: Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more

STAT

using its Accredo specialty pharmacy beginning in June , Reuters writes. Cigna said the move should save around $3,500 on average per year for some of the 100,000 Accredo patients using either Humira or biosimilar. monthly list price of Humira.

article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy Checkup, Health Plan and Insulin, Gross-to-Net Bubble Update, and Amazon Redux

Drug Channels

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy, Health Plans and Insulin, Gross-to-Net Bubble Update, CVS & 340B, and Amazon Redux

Drug Channels

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers.

article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy Checkup, Insulin Profits, Gross-to-Net Bubble Update, CVS & 340B, Amazon Redux, and the FDA Appraises Soup

Drug Channels

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone!

article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy Checkup, Insulin & Health Plans, Gross-to-Net Bubble Update, CVS & 340B, and Amazon Redux

Drug Channels

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers.

article thumbnail

Drug Channels News Roundup, May 2020: COVID-19 and Formularies, Retail-to-Mail Trends, ABC on Biosimilars, and Social Distancing the CVS Way

Drug Channels

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

article thumbnail

Drug Channels Outlook 2023 (NEW Live Video Webinar)

Drug Channels

Fein will share his latest thinking on a wide range of topics, including: Retail and specialty pharmacy trends Vertical integration and consolidation The Inflation Reduction Act of 2022 The Medicare Part D Redesign Biosimilars Discount cards and cash-pay pharmacies The growing impact of hospitals and health systems The 340B Drug Pricing Program Federal (..)